ORIC Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
De CEO ORIC Pharmaceuticals is Jacob Chacko, benoemd in May2018, heeft een ambtstermijn van 6.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.15M, bestaande uit 18.9% salaris en 81.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.03% van de aandelen van het bedrijf, ter waarde $ 6.37M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 4.6 jaar.
Belangrijke informatie
Jacob Chacko
Algemeen directeur
US$3.2m
Totale compensatie
| Percentage CEO-salaris | 18.9% |
| Dienstverband CEO | 6.5yrs |
| Eigendom CEO | 1.0% |
| Management gemiddelde ambtstermijn | 5.3yrs |
| Gemiddelde ambtstermijn bestuur | 4.6yrs |
Recente managementupdates
Recent updates
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Aug 21
ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation
Jul 29ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Jul 17We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
May 08ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01
Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$120m |
| Jun 30 2024 | n/a | n/a | -US$111m |
| Mar 31 2024 | n/a | n/a | -US$102m |
| Dec 31 2023 | US$3m | US$596k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$93m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$4m | US$572k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$91m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | US$7m | US$536k | -US$79m |
| Sep 30 2021 | n/a | n/a | -US$84m |
| Jun 30 2021 | n/a | n/a | -US$91m |
| Mar 31 2021 | n/a | n/a | -US$81m |
| Dec 31 2020 | US$6m | US$489k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$672k | US$456k | -US$27m |
| Dec 31 2018 | US$2m | US$290k | -US$21m |
Compensatie versus markt: De totale vergoeding ($USD 3.15M ) Jacob } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.20M ).
Compensatie versus inkomsten: De vergoeding van Jacob is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jacob Chacko (45 yo)
6.5yrs
Tenure
US$3,153,083
Compensatie
Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | US$186.87k | 0.32% $ 2.0m | |
| President | 6.5yrs | US$3.15m | 1.03% $ 6.4m | |
| Chief Financial Officer | 5.2yrs | US$1.45m | 0.12% $ 732.5k | |
| Chief Medical Officer | 6.2yrs | US$1.51m | 0.034% $ 208.1k | |
| Co-Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Co-Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Chief Scientific Officer | 5.3yrs | geen gegevens | geen gegevens | |
| General Counsel | 4.6yrs | geen gegevens | geen gegevens | |
| VP & Head of People | 2.2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development | 5.7yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | 6yrs | geen gegevens | geen gegevens | |
| Senior VP of Commercial & Medical Affairs | less than a year | geen gegevens | geen gegevens |
5.3yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ORIC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | US$186.87k | 0.32% $ 2.0m | |
| President | 6.5yrs | US$3.15m | 1.03% $ 6.4m | |
| Co-Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Co-Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 3yrs | US$140.37k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$133.87k | 0.029% $ 179.2k | |
| Independent Director | 4.8yrs | US$147.87k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$141.37k | 0% $ 0 |
4.6yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ORIC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).